-
Previous investigation of cervical cancer biology has revealed a dependence on VEGF, among other factors, for growth and metastases.
-
The author summarizes the protocols used at his institution to prevent adhesions in patients who were undergoing evaluation and treatment for significant pelvic pathology.
-
In this issue: Antiviral drugs and birth defects, bisphosphonates and esophageal cancer, naltrexone plus bupropion for weight loss, 2010-11 influenza vaccine, FDA Actions.
-
Although some aspects of vaginal birth after cesarean delivery (VBAC) have been covered in previous OB/GYN Clinical Alert issues, I cannot pass up an opportunity to comment on two papers appearing in the June issue of Obstetrics & Gynecology.
-
Carcinosarcoma of the uterus is a rare condition accounting for less that 4% of all uterine neoplasms. Previous work has identified that the most active single agents are platinum, ifosfamide, paclitaxel, and doxorubicin.
-
Without fanfare, the FDA approved oral tranexamic acid tablets (Lysteda), the first non-hormonal product cleared to treat heavy menstrual bleeding in the United States.
-
In this issue: Lorcaserin submitted for FDA review, FDA advisory panel votes against phentermine/topiramate, mixed vote on rosiglitazone, advisory panel votes to remove breast cancer indication from bevacizumab labeling, no increase in seizures found with DTaP vaccine, new REMS for quinine.
-
-
I love this article. It's relevant to our daily practice, but, more importantly, it verbalizes the same issues that both physicians and patients want clarified.
-
In this issue: Aggressive approach to CVD reduces MI, folic acid and vitamin B12 for CAD, corticosteroids for acute exacerbations of COPD, prescription drug abuse among young adults, and ARBs and cancer risk.
